AbbVie: 2024 first full year of competition by biosimilars in US. It'll really bite the following years, but sales will probably remain in low billions.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.